RPRX - Royalty Pharma PLC Stock Price, Fair Value and News

27.26USD-0.62 (-2.22%)Market Closed

Market Summary

USD27.26-0.62

Market Closed

-2.22%

RPRX Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)

RPRX Stock Price

View Fullscreen

RPRX RSI Chart

RPRX Valuation

Market Cap

12.2B

Price/Earnings (Trailing)

15.31

Price/Sales (Trailing)

5.46

EV/EBITDA

12.78

Price/Free Cashflow

4.67

RPRX Price/Sales (Trailing)

RPRX Profitability

EBT Margin

53.01%

Return on Equity

8.1%

Return on Assets

4.95%

Free Cashflow Yield

21.41%

RPRX Fundamentals

RPRX Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

-16.96%

Rev. Growth (Qtr)

-4.71%

RPRX Earnings

Earnings (TTM)

798.9M

Earnings Growth (Yr)

-98.6%

Earnings Growth (Qtr)

-99.03%

Breaking Down RPRX Revenue

Last 7 days

-2.9%

Last 30 days

-1.3%

Last 90 days

-8.9%

Trailing 12 Months

-18.9%

How does RPRX drawdown profile look like?

RPRX Financial Health

Current Ratio

12.52

Debt/Equity

0.62

Debt/Cashflow

0.43

RPRX Investor Care

Dividend Yield

2.97%

Dividend/Share (TTM)

0.81

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

1.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.2B	0	0	0
2023	2.4B	2.4B	2.3B	2.4B
2022	2.3B	2.3B	2.2B	2.2B
2021	2.4B	2.4B	2.5B	2.3B
2020	1.2B	1.6B	1.6B	1.9B
2019	1.2B	1.4B	1.6B	1.8B
2018	0	0	0	983.2M
2017	0	0	0	877.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Royalty Pharma PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	bassler bonnie l	acquired	37,483	30.2283	1,240	-
Mar 28, 2024	fernandez henry a	acquired	37,483	30.2283	1,240	-
Feb 20, 2024	riggs rory b	acquired	-	-	300,000	-
Jan 04, 2024	riggs rory b	sold	-983,504	27.5476	-35,702	-
Jan 03, 2024	riggs rory b	sold	-5,532,280	27.7867	-199,098	-
Jan 02, 2024	riggs rory b	sold	-6,707,080	28.5165	-235,200	-
Dec 29, 2023	bassler bonnie l	acquired	37,493	27.711	1,353	-
Dec 29, 2023	avara management ltd	sold	-1,845,410	28.0444	-65,803	-
Dec 29, 2023	fernandez henry a	acquired	37,493	27.711	1,353	-
Dec 28, 2023	avara management ltd	sold	-5,918,930	28.2038	-209,863	-

Which funds bought or sold RPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Plato Investment Management Ltd	new	-	1,163,480	1,163,480	0.12%
May 17, 2024	Advisory Resource Group	new	-	823,665	823,665	0.19%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-78.43	-8,987,480	2,733,330	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	2.13	1,859,990	19,711,800	0.03%
May 16, 2024	B. Riley Wealth Advisors, Inc.	new	-	435,597	435,597	0.01%
May 16, 2024	Tidal Investments LLC	added	28.21	765,154	2,740,300	0.04%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-14.31	-80,696	1,016,160	-%
May 15, 2024	Royal Bank of Canada	added	68.78	11,436,000	25,300,000	0.01%
May 15, 2024	AMUNDI	reduced	-40.2	-43,025,900	61,593,800	0.03%
May 15, 2024	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	added	2.97	139,677	1,373,000	0.01%

Are Funds Buying or Selling RPRX?

Are funds buying RPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPRX

No. of Funds

Unveiling Royalty Pharma PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.54%	37,997,522	SC 13G/A
Feb 13, 2024	general atlantic, l.p.	5.6%	26,259,141	SC 13G/A
Feb 09, 2024	morgan stanley	9.2%	41,159,749	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 13, 2023	general atlantic, l.p.	5.6%	26,244,741	SC 13G/A
Feb 10, 2023	morgan stanley	9.9%	43,775,398	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	1.59%	7e+06	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.08%	35,627,791	SC 13G/A
Oct 04, 2022	giuliani mario germano	2.7%	11,604,660	SC 13D/A

Recent SEC filings of Royalty Pharma PLC

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Royalty Pharma PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Royalty Pharma PLC News

Latest updates

Royalty Pharma PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.7%	568	596	536	538	684	566	573	536	562	576	586	555	573	759	538	511	128	457	464	156	-
Costs and Expenses	3913.6%	642	-16.83	385	289	205	1,048	381	158	342	422	283	-189	344	258	28.00	102	139	-874	-68.22	130	-
S&GA Expenses	-100.0%	-	59.00	57.00	48.00	86.00	73.00	51.00	52.00	52.00	46.00	49.00	45.00	43.00	50.00	51.00	43.00	38.00	23.00	26.00	30.00	-
R&D Expenses	0%	1.00	1.00	51.00	1.00	1.00	51.00	26.00	1.00	101	-	91.00	3.00	3.00	8.00	5.00	6.00	8.00	16.00	23.00	21.00	-
EBITDA Margin	-23.6%	0.61*	0.80*	0.24*	0.28*	0.34*	0.19*	0.48*	0.48*	0.61*	0.61*	0.69*	0.87*	0.79*	0.96*	1.81*	1.81*	2.01*	1.50*	1.12*	1.29*	1.51*
Interest Expenses	-6.4%	44.00	47.00	46.00	47.00	47.00	47.00	47.00	47.00	47.00	47.00	44.00	37.00	37.00	38.00	31.00	34.00	54.00	63.00	69.00	69.00	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-100.6%	-4.27	718	122	351	509	-610	220	492	128	54.00	222	807	159	367	624	602	109	1,447	440	179	-
EBT Margin	-26.6%	0.53*	0.72*	0.16*	0.20*	0.26*	0.10*	0.40*	0.40*	0.53*	0.54*	0.63*	0.81*	0.74*	0.88*	1.70*	1.66*	1.80*	1.36*	0.94*	1.09*	1.27*
Net Income	-99.0%	5.00	494	72.00	228	341	-456	143	305	52.00	8.00	102	441	69.00	171	582	442	38.00	1,420	409	152	-
Net Income Margin	-26.0%	0.36*	0.48*	0.08*	0.11*	0.14*	0.02*	0.23*	0.21*	0.26*	0.27*	0.32*	0.52*	0.53*	0.64*	1.52*	1.48*	1.67*	1.29*	0.86*	0.98*	1.16*
Free Cashflow	-14.0%	665	773	574	608	1,034	570	539	575	460	490	470	532	526	566	509	489	471	478	419	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-1.5%	16,131	16,382	15,856	17,121	17,074	16,813	17,673	17,740	17,379	17,516	17,732	16,515	15,914	16,020	15,991	15,686	14,068	12,450	11,370
Current Assets	22.4%	1,560	1,274	1,729	2,954	2,631	2,555	2,342	3,504	2,982	2,878	2,776	2,707	2,416	2,697	2,784	3,391	-	832	2,609
Cash Equivalents	76.7%	843	477	936	2,173	1,976	1,711	992	2,108	1,792	1,541	1,801	1,142	709	1,009	1,553	2,322	498	246	1,924
Liabilities	-0.5%	6,267	6,298	6,270	7,308	7,252	7,288	7,256	7,332	7,237	7,267	7,346	6,110	6,077	6,124	6,192	6,291	6,300	6,308	6,818
Current Liabilities	-22.8%	125	161	128	1,172	1,117	1,167	1,132	182	136	171	255	284	256	308	270	451	-	333	580
Long Term Debt	0.1%	6,139	6,135	6,131	6,127	6,123	6,119	6,115	7,106	7,101	7,096	7,091	5,826	5,821	5,817	5,812	5,730	-	5,956	6,238
LT Debt, Current	-	-	-	-	999	998	998	997	-	-	-	-	-	-	-	-	182	-	282	281
LT Debt, Non Current	-100.0%	-	6,135	6,131	6,127	6,123	6,119	6,115	7,106	7,101	7,096	7,091	5,826	5,821	5,817	5,812	5,730	-	5,956	6,238
Shareholder's Equity	-2.2%	9,864	10,084	9,585	9,814	9,822	9,525	10,416	10,408	10,142	10,249	10,387	10,405	9,837	9,896	9,799	9,395	7,163	6,141	4,552
Retained Earnings	-3.6%	2,427	2,518	2,135	2,253	2,217	1,965	2,505	2,446	2,225	2,255	2,321	2,292	1,924	1,921	1,807	1,571	-	2,825	1,216
Additional Paid-In Capital	1.6%	4,075	4,011	4,007	4,031	3,740	3,666	3,633	3,571	3,543	3,508	3,454	3,416	2,931	2,866	2,612	2,557	-	-	-
Shares Outstanding	0.2%	449	448	448	448	446	438	437	436	434	415	409	400	390	375	370	354	-	37.00	37.00
Minority Interest	-5.4%	3,364	3,558	3,446	3,532	3,868	3,897	4,264	4,381	4,364	4,472	4,594	4,672	4,955	5,077	5,347	5,238	-	36.00	64.00
Float	-	-	-	-	13,700	-	-	-	18,500	-	-	-	16,600	-	-	-	4,200	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-14.0%	665	773	574	608	1,034	570	539	575	460	490	470	532	526	566	509	489	471	478	419	-	-
Cashflow From Investing	91.3%	-86.65	-1,000	-450	-63.43	-558	415	-1,425	-30.18	11.00	-551	-845	126	-599	-832	-920	-244	-761	-62.82	-615	-	-
Cashflow From Financing	8.6%	-212	-231	-1,359	-347	-210	-265	-230	-228	-220	-198	1,034	-224	-226	-277	-357	1,579	543	-285	-280	-	-
Buy Backs	-100.0%	-	30.00	144	134	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RPRX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 567,978	$ 683,971
Operating expenses
Provision for changes in expected cash flows from financial royalty assets	583,600	118,804
Research and development funding expense	500	500
General and administrative expenses	57,652	85,695
Total operating expenses, net	641,752	204,999
Operating (loss)/income	(73,774)	478,972
Other expense/(income)
Equity in losses/(earnings) of equity method investees	14,149	(34,606)
Interest expense	44,232	46,950
Gains on derivative financial instruments	0	(7,090)
(Gains)/losses on equity securities	(77,730)	10,818
Gains on available for sale debt securities	(46,420)	(32,300)
Interest income	(7,417)	(16,702)
Other non-operating expense, net	3,685	2,813
Total other income, net	(69,501)	(30,117)
Consolidated net (loss)/income before tax	(4,273)	509,089
Income tax expense	0	0
Consolidated net (loss)/income	(4,273)	509,089
Net (loss)/income attributable to non-controlling interests	(9,051)	168,334
Net income attributable to Royalty Pharma plc	$ 4,778	$ 340,755
Earnings per Class A ordinary share:
Basic (in dollars per share)	$ 0.01	$ 0.76
Diluted (in dollars per share)	$ 0.01	$ 0.76
Weighted average Class A ordinary shares outstanding:
Basic (in shares)	448,623	445,612
Diluted (in shares)	597,479	607,251
Financial Royalty Assets
Revenues	$ 541,546	$ 664,687
Other Royalty Income
Revenues	$ 26,432	$ 19,284

RPRX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 843,000	$ 477,010
Financial royalty assets	660,482	738,438
Available for sale debt securities	29,000	18,300
Other royalty income receivable	22,227	22,405
Other current assets	5,010	18,040
Total current assets	1,559,719	1,274,193
Financial royalty assets, net	13,465,407	14,088,655
Equity securities	277,217	199,487
Available for sale debt securities	473,700	437,100
Equity method investments	350,355	375,894
Other assets	4,488	6,522
Total assets	16,130,886	16,381,851
Current liabilities
Distributions payable to legacy non-controlling interests	91,409	83,155
Accounts payable and accrued expenses	11,551	15,165
Interest payable	12,595	51,682
Other current liabilities	9,019	11,375
Total current liabilities	124,574	161,377
Long-term debt	6,139,376	6,135,285
Other liabilities	3,220	900
Total liabilities	6,267,170	6,297,562
Commitments and contingencies
Shareholders’ equity
Deferred shares, $0.000001 par value; issued and outstanding: 2024–388,927 and 2023–384,640	0	0
Additional paid-in capital	4,074,849	4,011,435
Retained earnings	2,427,448	2,517,583
Non-controlling interests	3,363,965	3,557,792
Treasury interests	(2,654)	(2,629)
Total shareholders’ equity	9,863,716	10,084,289
Total liabilities and shareholders’ equity	16,130,886	16,381,851
Class A Ordinary Shares
Shareholders’ equity
Common stock	45	45
Class B Ordinary Shares
Shareholders’ equity
Common stock	0	0
Class R Redeemable Shares
Shareholders’ equity
Common stock	$ 63	$ 63

About Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO	Mr. Pablo Gerardo Legorreta
WEBSITE	royaltypharma.com
INDUSTRY	Biotechnology

Royalty Pharma PLC Frequently Asked Questions

What is the ticker symbol for Royalty Pharma PLC? What does RPRX stand for in stocks?

RPRX is the stock ticker symbol of Royalty Pharma PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Royalty Pharma PLC (RPRX)?

As of Fri May 17 2024, market cap of Royalty Pharma PLC is 12.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers. The fair value of Royalty Pharma PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Royalty Pharma PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Royalty Pharma PLC a good stock to buy?

The fair value guage provides a quick view whether RPRX is over valued or under valued. Whether Royalty Pharma PLC is cheap or expensive depends on the assumptions which impact Royalty Pharma PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPRX.

What is Royalty Pharma PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RPRX's PE ratio (Price to Earnings) is 15.31 and Price to Sales (PS) ratio is 5.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPRX PE ratio will change depending on the future growth rate expectations of investors.